| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
7,216 |
5,870 |
$757K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
2,835 |
2,513 |
$629K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
7,895 |
6,670 |
$579K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
954 |
881 |
$369K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
5,692 |
4,439 |
$352K |
| 90837 |
Psychotherapy, 53 minutes with patient |
2,056 |
960 |
$160K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
3,302 |
3,042 |
$126K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
910 |
810 |
$116K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
3,694 |
1,175 |
$112K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
763 |
554 |
$95K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,429 |
2,117 |
$82K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
976 |
718 |
$69K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,363 |
1,337 |
$62K |
| 80061 |
Lipid panel |
3,339 |
3,319 |
$38K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
911 |
882 |
$38K |
| 80053 |
Comprehensive metabolic panel |
10,200 |
8,881 |
$36K |
| 71046 |
Radiologic examination, chest; 2 views |
757 |
726 |
$33K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
1,180 |
1,017 |
$32K |
| 84443 |
Thyroid stimulating hormone (TSH) |
4,166 |
4,030 |
$32K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
123 |
118 |
$29K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
471 |
471 |
$29K |
| 71045 |
Radiologic examination, chest; single view |
564 |
532 |
$29K |
| 36415 |
Collection of venous blood by venipuncture |
14,696 |
12,333 |
$28K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
10,492 |
9,018 |
$27K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
702 |
551 |
$26K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,022 |
999 |
$22K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
1,176 |
1,171 |
$21K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,128 |
1,035 |
$21K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
934 |
380 |
$17K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,867 |
1,737 |
$17K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
302 |
285 |
$16K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
706 |
642 |
$16K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
459 |
438 |
$14K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,338 |
2,321 |
$14K |
| 73630 |
|
975 |
765 |
$13K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
110 |
106 |
$12K |
| 97161 |
|
149 |
149 |
$10K |
| 87634 |
|
292 |
283 |
$10K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
211 |
122 |
$9K |
| 70450 |
Computed tomography, head or brain; without contrast material |
130 |
128 |
$9K |
| 81001 |
|
6,150 |
5,673 |
$7K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
190 |
89 |
$6K |
| 99215 |
Prolong outpt/office vis |
59 |
45 |
$5K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,587 |
1,472 |
$5K |
| 84439 |
|
1,051 |
1,025 |
$5K |
| 80306 |
|
899 |
839 |
$5K |
| Q3014 |
Telehealth originating site facility fee |
304 |
281 |
$4K |
| 83735 |
|
2,403 |
2,047 |
$4K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
205 |
205 |
$3K |
| 82607 |
|
421 |
410 |
$3K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
40 |
40 |
$3K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
644 |
592 |
$3K |
| 81025 |
|
1,030 |
971 |
$3K |
| 20610 |
|
23 |
12 |
$3K |
| 87186 |
|
759 |
713 |
$3K |
| 82746 |
|
339 |
326 |
$3K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
96 |
94 |
$3K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
823 |
749 |
$3K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
252 |
226 |
$2K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
139 |
137 |
$2K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
139 |
137 |
$2K |
| 86140 |
|
2,202 |
1,918 |
$2K |
| 90834 |
Psychotherapy, 45 minutes with patient |
33 |
27 |
$2K |
| 87070 |
|
372 |
361 |
$2K |
| 85610 |
|
1,563 |
1,248 |
$1K |
| 87077 |
|
305 |
292 |
$1K |
| 87581 |
|
110 |
106 |
$995.09 |
| 87486 |
|
110 |
106 |
$995.09 |
| 71271 |
|
12 |
12 |
$967.08 |
| 82728 |
|
143 |
139 |
$933.50 |
| 83690 |
|
1,168 |
1,031 |
$920.87 |
| 84145 |
|
693 |
576 |
$615.39 |
| 82150 |
|
870 |
766 |
$544.58 |
| 84703 |
|
472 |
441 |
$487.73 |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
28 |
27 |
$445.34 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
309 |
263 |
$388.59 |
| 82550 |
|
853 |
775 |
$386.77 |
| 86803 |
|
38 |
38 |
$313.33 |
| 83605 |
|
783 |
660 |
$223.66 |
| 84484 |
|
888 |
677 |
$160.14 |
| A9270 |
Non-covered item or service |
317 |
292 |
$144.00 |
| 85651 |
|
109 |
102 |
$135.57 |
| 85027 |
|
41 |
40 |
$119.36 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
15 |
15 |
$109.70 |
| 86900 |
|
14 |
12 |
$91.09 |
| 85730 |
|
221 |
211 |
$75.06 |
| 85652 |
|
65 |
61 |
$73.47 |
| 87088 |
|
25 |
24 |
$64.96 |
| 83540 |
|
12 |
12 |
$42.93 |
| 85379 |
|
51 |
51 |
$7.68 |
| 87040 |
|
128 |
120 |
$6.48 |
| 94761 |
|
132 |
123 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
576 |
567 |
$0.00 |
| J7050 |
Infusion, normal saline solution, 250 cc |
122 |
119 |
$0.00 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
37 |
37 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
210 |
186 |
$0.00 |
| 82962 |
|
12 |
12 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
108 |
104 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
271 |
248 |
$0.00 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
291 |
260 |
$0.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
15 |
12 |
$0.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
42 |
40 |
$0.00 |
| 86901 |
|
14 |
12 |
$0.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
424 |
367 |
$0.00 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
481 |
311 |
$0.00 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
921 |
854 |
$0.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
359 |
354 |
$0.00 |
| A4216 |
Sterile water, saline and/or dextrose, diluent/flush, 10 ml |
29 |
24 |
$0.00 |